

**A pilot randomized controlled trial comparing effectiveness of prism glasses, visual search training and standard care in hemianopia**

Rowe, F.J.; Conroy, E.J.; Bedson, E.; Cwiklinski, E.; Drummond, A.; García-Fiñana, M.; Howard, C.; Pollock, A.; Shipman, T.; Dodridge, C.; MacIntosh, C.; Johnson, S.; Noonan, C.; Barton, G.; Sackley, C.

*Published in:*  
Acta Neurologica Scandinavica

*DOI:*  
[10.1111/ane.12725](https://doi.org/10.1111/ane.12725)

*Publication date:*  
2017

*Document Version*  
Author accepted manuscript

[Link to publication in ResearchOnline](#)

*Citation for published version (Harvard):*

Rowe, FJ, Conroy, EJ, Bedson, E, Cwiklinski, E, Drummond, A, García-Fiñana, M, Howard, C, Pollock, A, Shipman, T, Dodridge, C, MacIntosh, C, Johnson, S, Noonan, C, Barton, G & Sackley, C 2017, 'A pilot randomized controlled trial comparing effectiveness of prism glasses, visual search training and standard care in hemianopia', *Acta Neurologica Scandinavica*, vol. 136, no. 4, pp. 310-321. <https://doi.org/10.1111/ane.12725>

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

If you believe that this document breaches copyright please view our takedown policy at <https://edshare.gcu.ac.uk/id/eprint/5179> for details of how to contact us.

## **A pilot randomised controlled trial comparing effectiveness of prism glasses, visual search training and standard care in hemianopia**

Fiona J Rowe, PhD<sup>1</sup>, Elizabeth J Conroy, PhD<sup>2</sup>, Emma Bedson, PhD<sup>3</sup>, Emma Cwiklinski, PhD<sup>3</sup>, Avril Drummond, PhD<sup>4</sup>, Marta García- Fiñana, PhD<sup>2</sup>, Claire Howard, MMedSci<sup>5</sup>, Alex Pollock, PhD<sup>6</sup>, Tracey Shipman, DBO<sup>7</sup>, Caroline Dodridge, DBO<sup>8</sup>, Claire MacIntosh, DBO<sup>8</sup>, Stevie Johnson, DBO<sup>9</sup>, Carmel Noonan, FRCSI, FRCOphth<sup>10</sup>, Graham Barton, FRCP<sup>11</sup>, Catherine Sackley, PhD<sup>12</sup>

- 1 Department of Health Services Research, University of Liverpool, Liverpool L69 3GB, rowef@liverpool.ac.uk
- 2 Department of Biostatistics, University of Liverpool, Liverpool L69 3GA, ejconroy@liverpool.ac.uk, martaf@liverpool.ac.uk
- 3 Clinical Trials Research Unit, University of Liverpool, Liverpool L69 3GL, ebedson@liverpool.ac.uk, emmalc@liverpool.ac.uk
- 4 School of Health Sciences, University of Nottingham, Nottingham NG7 2UH, avril.drummond@nottingham.ac.uk
- 5 Department of Orthoptics, Salford Royal NHS Foundation Trust, Manchester M6 8HD, howardc@liverpool.ac.uk
- 6 Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, Glasgow, alex.pollock@gcu.ac.uk
- 7 Department of Orthoptics, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, tracey.shipman@sth.nhs.uk

- 8 Department of Orthoptics, Oxford University Hospitals NHS Trust, Oxford OX3 9DU, caroline.dodridge@ouh.nhs.uk, Claire.macintosh2@ouh.nhs.uk
- 9 Eye Clinic Impact Team, Royal National Institute for the Blind, Birmingham B1 1BN, stevie.johnson@rnib.org.uk
- 10 Department of Ophthalmology, Aintree University Hospital NHS Foundation Trust, Liverpool L9 7AL, carmel.noonan@aintree.nhs.uk
- 11 Department of Elderly Care, Warrington and Halton Hospitals NHS Foundation Trust, Warrington WA5 1QC, graham.barton@whh.nhs.uk
- 12 Division of Health and Social Care, King's College, London WC2B 5RL, Catherine.sackley@kcl.ac.uk

**Corresponding author and address for reprints:**

Dr Fiona Rowe,

Department of Health Services Research,

University of Liverpool,

Liverpool L69 3GB.

T: 0151 7944956,

E: rowef@liverpool.ac.uk

Word count: 3756

Number of figures: 2

Number of tables: 7

Running head: VISION hemianopia trial results

### **Financial support**

This trial was funded by the Stroke Association, UK. The sponsor or funding organization had no role in the design or conduct of this research.

### **Conflict of interests**

No conflicting relationship exists for any author

### **Competing interests**

This trial is funded by the UK Stroke Association which includes salaries for EC.

The sponsor (University of Liverpool Research Support Office) and funder (the Stroke Organisation) had no role in the study design, collection, management, analysis, interpretation of data, writing of the report; and the decision to submit the protocol for publication.

## **Author contributions**

FR, GB, RB, AD, MGF, SJ, CM, CN, AP, JR and CS conceived of the study, participated in the design and coordination, and helped to draft the manuscript. EB, CD, CH and TS participated in the coordination and helped to draft the manuscript. MGF supervised the statistical analysis. EJC wrote the statistical analysis plan, performed the statistical analysis, participated in the coordination and data monitoring and helped to draft the manuscript. EC participated in the coordination, performed data entry and helped to draft the manuscript. All authors read and approved the final manuscript.

## **Abbreviations**

VISION: **v**ision **i**mpairment **i**n **s**troke:**i**ntervention **o**r **n**ot

UK: United Kingdom

NHS: National health Service

RNIB: Royal National Institute for the Blind

## **Abstract**

Objective: Pilot trial comparing prism therapy and visual search training, for homonymous hemianopia, to standard care (information only).

Methods: Prospective, multicentre, parallel, single-blind, three-arm RCT across fifteen UK acute stroke units.

Participants: Stroke survivors with homonymous hemianopia.

Interventions: Arm a (Fresnel prisms) for minimum 2 hours, 5 days/week over 6-weeks. Arm b (visual search training) for minimum 30 minutes, 5 days/week over 6-weeks. Arm c (standard care-information only).

Inclusion criteria: Adult stroke survivors (>18 years), stable hemianopia, visual acuity better than 0.5logMAR, refractive error within  $\pm 5$  Dioptres, ability to read/understand English, and provide consent.

Outcomes: Primary outcomes were change in visual field area from baseline to 26 weeks and calculation of sample size for a definitive trial. Secondary measures included Rivermead Mobility Index, Visual Function Questionnaire 25/10, Nottingham Extended Activities of Daily Living, Euro Qual, Short Form-12 questionnaires and Radner reading ability. Measures were post-randomisation at baseline and 6, 12, 26 weeks.

Randomisation: Randomisation block lists stratified by site and partial/complete hemianopia.

Blinding: Allocations disclosed to patients. Primary outcome assessor blind to treatment allocation.

Results: 87 patients were recruited: 27 - Fresnel prisms, 30 – visual search training and 30 - standard care. 69% male; mean age 69 years (SD 12). At 26 weeks, full results for 24, 24 and 22 patients respectively were compared to baseline. Sample size

calculation for a definitive trial determined as 269 participants per arm for a 200 degree<sup>2</sup> visual field area change at 90% power. Non-significant relative change in area of visual field was 5%, 8% and 3.5% respectively for the three groups. Visual Function Questionnaire responses improved significantly from baseline to 26 weeks with visual search training (60 (SD19) to 68.4 (SD20)) compared to Fresnel prisms (68.5 (SD16.4) to 68.2 (18.4): 7% difference) and standard care (63.7 (SD19.4) to 59.8 (SD22.7): 10% difference),  $p=0.05$ . Related adverse events were common with Fresnel prisms (69.2%; typically headaches).

Conclusions: No significant change occurred for area of visual field area across arms over follow-up. Visual search training had significant improvement in vision-related quality of life. Prism therapy produced adverse events in 69%. Visual search training results warrant further investigation.

The trial is funded by the UK Stroke Association. Trial Registration: Current Controlled Trials ISRCTN05956042.

**Keywords:** Homonymous hemianopia; Pilot trial; Prism therapy; Randomised controlled trial; Standard care; Stroke; Visual search training

## **Introduction**

Homonymous hemianopia results in loss of one half of the visual field in both eyes [1,2]. The reported prevalence of visual field loss following stroke has been as high as 63% [3] in hospital populations although estimates vary widely as the proportion testing positive is highly dependent on time post stroke. Visual field defects can seriously impact functional ability and quality of life following stroke [4,5]. Patients with visual field defects have an increased risk of falling [6], impaired ability to read, poor mood and institutionalization [6-9]. Visual field loss may impact on a patient's ability to participate in rehabilitation, and may ultimately result in poor long term recovery [8]. Visual field loss can result in accidents or injuries which have subsequent cost implications to the NHS and the patient [10].

Two key interventions commonly used in the clinical setting to improve vision in hemianopia are visual search compensatory training and provision of prisms [11]. A Cochrane systematic review [11] evaluated the interventions for homonymous hemianopia and found evidence in favour of visual search training. Subsequently, Aimola and colleagues [12] conducted a trial of visual search training for homonymous hemianopia and reported evidence of improved quality of life in the intervention group. The Cochrane review did not find sufficient evidence for prisms as an intervention for hemianopia.

The aim of this pilot trial was to compare visual rehabilitation interventions with NHS standard care, in patients with hemianopia following stroke. We wished to explore whether visual rehabilitation was more effective than standard care (advice only) at



improving functional outcome in patients with hemianopia following stroke, and whether prism therapy or visual search therapy was more effective at improving functional outcome in patients with hemianopia following stroke.

## **Methods**

### ***Trial design***

VISION was a randomised controlled, multicentre pilot trial with NHS research ethical approval (10/H1003/119). The trial protocol is reported elsewhere [13].

### ***Participants***

Patients were eligible for inclusion if they met the criteria:

- a. 18 years of age or older;
- b. Best corrected visual acuity of 0.5 or better in each eye at distance;
- c. Stable homonymous hemianopia (partial or complete) induced by recent stroke, defined following WHO guidelines, present over 2 weeks (to exclude rapid recovery cases) but less than 26 weeks prior to randomisation;
- d. Refractive error within  $\pm 5$  Dioptres;
- e. Willing and able to give consent for the study;
- f. Prior to stroke able to read and understand English.

Patients were not eligible for inclusion if they were:

- a. unable to consent due to severe cognitive impairment;
- b. assessed to have ocular motility impairment and/or visual inattention in addition to the visual field impairment; or
- c. had pre-existent visual field impairment due to previous stroke.

Participants were recruited from stroke units based in 15 United Kingdom (UK) National Health Service (NHS) Trusts. Potentially eligible participants were identified by stroke research nurses, and screened for inclusion by a local principal investigator (a qualified orthoptist registered with the health and Care Professions Council, UK). Participants eligible for inclusion, and providing consent, attended for a baseline assessment, which included assessment and documentation of patient demographics, visual signs and symptoms, visual acuity measures, any additional ocular problems, comorbidity, severity of stroke and level of disability.

### ***Recruitment and randomisation***

Participants were individually randomised to one of three treatment groups using a secure (24-hour) web based randomisation programme. Randomisation lists were generated using block randomisation stratified by centre and degree of hemianopia (partial

or complete) with treatment allocation ratio of 1:1:1. The local PI (orthoptist) obtained the treatment allocation and subsequently assigned the participant to the treatment arm.

### ***Interventions***

#### *Treatment A: Fresnel prisms*

Participants were assessed and given sector Fresnel prisms of 40 prism dioptre strength on their glasses (or plain glasses if not already worn) [14]. Separate prism segments were used as a mechanical displacement to expand the upper and lower quadrants. Full fitting details are detailed in the protocol [13]. Participants were advised to wear the prisms for a minimum of 2 hours daily, for a minimum six weeks, from prism affixation; after this they could elect to continue treatment if wished.

#### *Treatment B: Visual search training*

Participants were assessed and provided with visual search training. This comprised an A4 landscape card with horizontal and diagonal numbered circles radiating out from a central fixation target. Full instructions for training are detailed in the protocol [13]. Participants were instructed to continually scan between the various targets for 30 minutes daily for a minimum six weeks, after which they could elect to continue treatment if they wished. Participants were instructed on the search exercises to ensure their understanding of doing this training. In addition, printed instructions were provided with the visual training target cards.

#### *Treatment C: Control - Standard Care (Information Only)*

Participants were given information leaflets from the UK Stroke Association and the UK Royal National Institute for the Blind (RNIB) about visual impairment following stroke.

Participants in all treatment groups received these information leaflets. Details of usage of the prisms and visual search training were collected by diaries, completed daily by participants.

### ***Outcomes***

Outcomes were assessed at baseline, 6, 12 and 26 weeks. The primary clinical outcome was relative change in visual field area (measured in degrees<sup>2</sup>) from baseline to 26 weeks and, based on this change, a sample size calculation for a future definitive trial. Secondary clinical outcomes, assessed by the orthoptist, were reading ability (speed and accuracy). Secondary clinical outcomes, reported by patients, were assessed through questionnaire booklets. [13]. Further key objectives of this pilot trial were to test the operationalisation of the intervention and the study outcome measures [13, 15].

### **Sample size calculation**

A sample size calculation was estimated for repeated measures analysis of covariance [16], using the data generated on visual field assessment.

## **Visual field assessment**

A blinded qualified Orthoptist assessed visual field area. An Esterman strategy was used for quantitative visual field assessment with standard fixation monitoring strategies of fixation loss, false positive and false negative responses. This was done using either:

- The Esterman programme on Humphrey or Octopus perimetry,
- The III4e target on Goldmann with additional checks of static points in the central visual field.

A template for Goldmann perimetry was supplied for standardisation to match the Esterman strategy on Humphrey and Octopus perimetry. A binocular visual field was measured first followed by monocular assessment of the right and left eyes. Visual fields were performed without prisms in place in the *Fresnel prism* arm. Where it was not possible to use either of these methods then the standardised confrontation method was used. Whichever method used at baseline was repeated at every follow up visit. Where the confrontation method was used at baseline one of the above quantitative methods was used at the follow-up if possible in addition to repeating the confrontation method.

## **Reading Ability**

Reading ability, assessed using the Radner reading test, is reported as time taken to read (seconds) and number of incorrect words from the 14 word passage [17].

### **Patient Completed Outcome Measures**

Participants completed a questionnaire booklet containing the following outcome measures:

- a. Visual function questionnaire (VFQ 25-10) [18]
- b. Rivermead mobility index (RMI) [19]
- c. Nottingham extended activities of daily living assessment (NEADL) [20]
- d. Euro Qual [21]
  - i. 5D (EQ-5D)
  - ii. VAS score (EQ-VAS)
- e. Short Form -12 (SF-12) [22]
  - i. Physical component summary (PCS)
  - ii. Mental component summary (MCS)

### ***Statistical Analysis***

There were insufficient data to carry out a formal power calculation to determine sample size for this trial, a sample size of 105 participants was considered sufficient to reach pilot objectives [13].

Outcome data were analysed according to the intention-to-treat principle. Safety analyses included all patients who were randomised to and received treatment. A p-value of 0.05 is considered significant, however as this is a pilot study not powered to identify differences, results will be interpreted with caution. Additionally, rather than adjust for multiplicity relevant results from other studies will be taken into account in the interpretation of results.

The statistical analysis plan, written by the trial statisticians and agreed by other members of the trial management group (TMG) and independent oversight committees: data and safety monitoring committee (DSMC) and the trial steering committee (TSC), prior to any comparative analyses together is available on request from the authors. No imputation methods were used for missing data and all patients who withdrew from the trial were encouraged to complete follow up.

All analyses were done with SAS software version 9.2. The primary feasibility outcome of sample size calculation was calculated for a repeated measures analysis of covariance [16]. Data collected from the trial were used to estimate the standard deviation, estimate of correlation and the loss to follow up rate for the main trial. All outcomes were summarised using descriptive statistics,

split by treatment, at baseline and 26 week follow up. The primary efficacy outcome was relative change in area of visual field assessment (VFA), defined as the difference in VFA from baseline to 26 weeks follow up, divided by the maximum possible VFA score for each method, and was analysed using ANOVA, controlling for treatment. A sensitivity analysis was performed on the VFA using ANCOVA for the modal assessment method (see Outcomes – Visual Field Assessment). Patient reported secondary outcomes: VFQ 25-10; RMI; NEADL; EQ-VAS and SF-12: PCS and MCS, reported at 26 week follow up, were compared using analysis of covariance, controlling for treatment and baseline assessment. EQ-5D and Radner Reading Score were summarised using only descriptive statistics,

## **Results**

### ***Recruitment and characteristics***

Recruitment and screening have been reported elsewhere [23]. In summary, 1171 patients were assessed for eligibility between 17<sup>th</sup> May 2011 and 9<sup>th</sup> September 2013. Of these, 993 patients (84.8%) did not meet the inclusion criteria, 91 patients declined to participate (7.8%) leaving 87 patients in the study (7.4%). The reasons for not being eligible and for refusing to consent were recorded and published [23].



In May 2012, the team noted that the proportion of eligible patients was lower than expected and this was slowing recruitment. Upon reviewing the accumulating recruitment data, the IDSMC recommended extending recruitment by one year and advised that the initial target sample size of 105 be reduced to 90 participants, of which 60 would be needed to complete the study. The TSC agreed with this proposal and the TMG actioned this amendment in June 2012. Figure 1 shows the cumulative recruitment graph, indicating *expected*, *revised expected* and *actual* recruitment by month.

At the end of the recruitment period, 27, 30 and 30 patients were randomised to *Fresnel prisms*, *Visual search training* and *standard care* respectively. Two patients (2/87, 2.3%) withdrew from data analysis and follow up; nine (9/87, 10.3%) from follow up only and five (5/87, 5.7%) were lost to follow up, of which four were from the standard arm (4/5, 80.0%). There was 24 (24/27, 88.9%), 25 (25/30, 83.3%) and 22 (22/30, 73.3%) patients in the *Fresnel prisms*, *Visual search training* and *standard care* respectively at 26 week follow up (see Figure 2).

Patient demographic and clinical characteristics at baseline are provided in Table 1 and 2. There were no notable differences at baseline between three arms. The population consisted primarily of white (97.6%) males (69.4%) randomised, on average, 11 weeks post ischaemic (95.3%) stroke (late recruitment relating to the requirement for stable, non-recovering hemianopia). The infarct was mostly classified unilateral (43.5% left; 54.1% right).

### ***Sample size outcome***

Table 3 provides the sample size needed per arm to detect a minimally clinically important difference in visual field between per arm for a given power. Predictions are provided for three values of the minimally clinically important difference (200, 400 and 600 degrees<sup>2</sup>) and for three levels of power (90%, 80% and 50%). 80% (70/87) of patients had full data at baseline and 26 weeks. Thus the required number of patients to be recruited was calculated as 1.25 times ( $=1/0.8$ ) the sample size shown in Table 3. Most recruiting sites used the Humphrey Static methods, with 33 in 70 (47.1%) patients having their VFA assessed using this method. Computing the sample size in the same way for patients being assessed by this method only reduces the number required (Table 3).

### ***Primary clinical outcome***

There was some variability in baseline relative change in visual field area across treatment arm and by method (Table 4), particularly those methods used most frequently. For the *Humphrey Static Esterman* method, the mean baseline visual field area was one-third lower in the *standard care* arm (955.8 degrees) when compared to the *visual search training* or *Fresnel prism* arm; 1428.9 degrees and 1382.5 degrees respectively. For the *Octopus Static Esterman* method, the mean baseline visual field was 44.2% and 18.4% higher in the *standard care* arm when compared to the *visual search training* and *Fresnel prism* arm respectively. These differences can be explained by the large within-group variances of visual field expected with a relatively low sample size per method of assessment and per arm.

The mean values of *relative* change in visual field area are given in Table 5, which shows a non-significant average minimal increase in visual field at 26 weeks of 5%, 8% and 3.5% for *Fresnel prisms*, *Visual search training* and *standard care*, respectively (p-values >5%, <5% and >5%, respectively).

### ***Secondary clinical outcomes***

Change in functional activity was evaluated as a secondary analysis. Visual function (using the VFQ 25-10) improved at 26 weeks in the *visual search training* arm (60 (SD19) to 68.4 (SD20) when compared to the *Fresnel Prisms* (68.5 (SD16.4) to 68.2 (18.4) and *standard care* arms ((63.7 (SD19.4) to 59.8 (SD22.7): Table 6, ANCOVA p=0.05). No evidence of differences across arms were found for any of the other secondary outcomes, including functional mobility (ANCOVA p=0.36, extended daily level index (ANCOVA p=0.93), EQ-5D VAS score (ANCOVA p=0.60), change of general health status (ANCOVA p=0.51), reading speed and reading accuracy.

### ***Compliance***

There were 73 protocol deviations in 58 patients (68.2% overall: 77% in the *Fresnel prism* arm, 93% in the *visual search* arm and 34.5% in the *standard care* arm). The majority of deviations (n=41, 56.2%) related to lack of compliance in the intervention arms (e.g., prism not worn a minimum of 2 hours daily for 6 weeks or visual exercises not carried out for 30 minutes daily for 6 weeks).

Compliance level was similar across the intervention arms. Patients in the Fresnel prisms arm wore the prisms during 27 days on average, and patients in the visual search training arm followed the visual search exercises 28 days on average. The protocol deviations in the standard group (n=10) were all related to timing and attendance at follow up visits.

Eighteen patients (69.2%) in the *Fresnel prisms* arm experienced a total of 42 adverse events of which 28 were classified as headache (Table 7). Two patients (6.7%) in the *visual search training* arm experienced seven adverse events (6 fatigue, 1 headache). No adverse events were recorded for in the standard care arm.

Continuation of treatment was greater in the visual search arm than in the Fresnel prisms arm. In the visual search arm, 24 of 25 patients continued the intervention after 6 weeks, 21 of 25 after 12 weeks and 10 of 25 patients after 26 weeks. This was in comparison to 14 of 26 patients in the Fresnel prism arm after 6 weeks, 12 of 23 after 12 weeks and 5 of 24 patients after 26 weeks.

## **Discussion**

Our primary clinical outcome measure was based on formal quantitative visual field assessment. Because of the multi-centre nature of the trial, a variety of visual field assessment methods were used as different hospitals had access to different perimeters. For future phase III trials using multiple visual field assessment methods, our sample size estimation is a maximum of 269 participants

per arm for a minimum clinically important difference of 200 degree<sup>2</sup> of visual field area relative change. Future trials using just one visual field assessment method require a sample size of a maximum of 132 participants for each arm.

The primary clinical outcome measure for this trial was relative change in visual field area from baseline to 26 weeks. A Cochrane systematic review of interventions for post-stroke visual field loss concluded that, generally, interventions for homonymous hemianopia did not result in improvement of visual field [11]. Our results similarly showed minimal non-significant change in visual field across all 3 arms of 5, 8 and 3.5%. We considered that a change of 15% in visual field area would be clinically significant. The insignificant change in visual field was expected given the deliberate recruitment of stable hemianopes to the trial. Other trials recruiting stable hemianopias also report no significant change to extent of visual field loss [12,24].

Published evidence relating to the effectiveness of interventions for post-stroke visual field loss is limited. Pollock and colleagues [11] concluded from their systematic review that compensatory scanning training interventions may be more beneficial than a placebo or control intervention at improving specific tasks. More recently, Aimola and colleagues [12] conducted a randomised controlled trial of visual exploration versus sham training and reported significant improvement in vision-related quality of life questionnaire scores following the intervention in comparison to sham training. They found no significant objective improvement noted in activity of daily living tasks. Our secondary clinical outcome measures included a range of questionnaires and indices to measure vision-related and health-related quality of life and activities of daily living. The only outcome measure to show a statistically significant change was vision-related quality of life (VFQ25/10).

Pollock and colleagues [11] found insufficient evidence to reach conclusions about the effectiveness of prisms; one more recent trial [24] compared real versus sham prism training. Their analysis of mobility questionnaire results showed no significant difference in real versus sham prism use. Our data showed no significant difference in motility questionnaire results. However, we noted a range of adverse events related to treatment which were greatest for the Fresnel prism arm (69.2%) versus the visual search training arm (6.7%). There were no adverse events for standard care.

Evaluation of recruitment and consent has been conducted for this trial and published previously [23]. We experienced greater recovery for hemianopia than previously reported in the literature and this should be taken into consideration when planning future trials with options to increase number of participating recruitment centres.

Adverse events reported with Fresnel prism therapy included headaches, difficulties with navigation, double vision, optical glare/aberrations and visual confusion, similar to events reported in previous trials [14,24]. Headaches were the most common adverse event for Fresnel prisms. We acknowledge that headaches can also be a post-stroke symptom. However, in this trial, given that headaches were not a symptom reported by patients receiving standard care and uncommon in those receiving visual search training, they were attributed to the Fresnel prism treatment. Given the extent and range of adverse events reported with prism wear, caution must be exercised if prescribing prism glasses as an intervention for homonymous hemianopia.

Adverse events for visual search training were minimal and consisted of fatigue and headache. To help minimise these potential side effects training periods should be curtailed to shorter accumulated periods rather than one long training session.

We used treatment diaries to capture patient use of interventions and extracted data from these and the case report forms as to whether patients voluntarily chose to continue their intervention beyond the minimum set treatment period of 6 weeks. More patients in the visual search arm voluntarily opted to continue their intervention than patients in the Fresnel prism arm.

We noted 73 protocol deviations. For the intervention arms, these largely related to compliance with the treatment duration although no significant difference was found in the level of compliance in both intervention arms. In future trials participants could be encouraged to break up their treatment duration per day as also suggested for reduction of adverse events; for example of having 3 shorter blocks of treatment per day instead of only one large block of treatment. For standard care most deviations related to follow-up visits taking place outside the time windows stipulated by the protocol. When planning future trials consideration should be given to regular telephone contact with patients to encourage on-going compliance with treatment and with timely reminders of upcoming review visits. This may also help with reducing loss to follow-up cases.

### ***Considerations***

A potential limitation of the trial was the need to use different visual field perimeters, and perimetrists, across recruitment sites for the primary outcome visual field measurements. A consideration in future trials would be to use just one perimeter type or consider alternative primary outcome measures. Given that visual fields did not change significantly and requires patients to attend follow-up appointments at hospital eye clinics (a potential deterrent to trial participation) an appropriate alternative primary outcome measure

may be a vision-related quality of life questionnaire such as the VFQ25 although there are many other questionnaires to choose from dependent on whether a health-related or condition-specific questionnaire is required [25].

With regard to generalizability, as this is a pilot trial, results should be interpreted with caution [26]. Although we found a statistically significant improvement in VFQ25 for visual search training, our trial was not powered for this. Nonetheless, the clinical differences are encouraging and warrant further investigation.

There remains insufficient evidence to reach conclusions about whether prisms are an effective intervention, and this study provides evidence of a high rate of adverse events associated with prism use. Clinicians with expert knowledge relating to prisms may consider their use for individual patients, but clinicians and patients both should be fully aware of potential adverse events and have a clear understanding relating to prism use.

## **Conclusions**

Our visual search training or Fresnel prism interventions for hemianopia produced minimal change in visual field area over the 26-week follow-up period. Visual search training produced a significant improvement in vision-related quality of life but not for other activity of daily living tasks. There were no significant improvements for any quality of life measure in our Fresnel prism arm. For the visual search arm, our participants reported a low percentage of adverse events, many continued with training and we found a significant change in quality of life. This must be interpreted with caution given our low sample size



There are a number of considerations in relation to planning future trials. Assessing change in visual field which required formal visual field assessment using a variety of perimeter types. It would help to limit assessment to one method or alternatively remove this as an outcome measure. We experienced low recruitment initially but took measures to improve this with increased number of recruitment centres and met the revised target for recruitment.

## **Acknowledgements**

FR had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

We should like to thank the patients and staff who participated in this trial and the following collaborators and investigators:

Isabel Ash, Conrad Beacham, Rachel Breen, Judith Burn, Carol Buckley, Joanne Gardiner, Henrietta Holmes-Smith, Sandra Knowles, Tallat Maan, Sonia MacDiarmid, Lorraine North, Leonie Ripley, Claire Scott, Sarah Spencer, Andrew Twigg, Carole-Anne Vince, Data Monitoring Committee (Cicely Freeman, Irene Stratton, David Wright), Trial Steering Committee (Darren Brand, Catie Bunce, Anne-Marie Mackay, Sarah Peel)

## **References**


1. ROWE FJ, VIS GROUP. Visual impairment following stroke. Do stroke patients require vision assessment? *Age and Ageing*. 2009; 38: 188-193
2. KERKHOFF G. Restorative and compensatory therapy approaches in cerebral blindness – a review. *Restorative Neurology Neuroscience*. 1999; 15: 255-271
3. GRAY CS, FRENCH JM, BATES D, et al. Recovery of visual fields in acute stroke: homonymous hemianopia associated with adverse prognosis. *Age and Ageing*. 1989; 18: 419-21
4. JONGBLOED L. Prediction of function after stroke: a critical review. *Stroke*. 1986; 17: 765-776
5. DOMBOVY ML, SANDOK BA, BASFORD JR. Rehabilitation for stroke: a review. *Stroke*. 1986; 17: 363-369
6. RAMRATTAN RS, WOLFS RC, PANDA-JONAS S et al. Prevalence and causes of visual field loss in the elderly and associations with impairment in daily functioning: the Rotterdam Study. *Archives of Ophthalmology*. 2001; 119: 1788–94
7. KAPLAN J, HIER DB. Visuospatial deficits after right hemisphere stroke. *American Journal of Occupational Therapy*. 1982; 36: 314–21.
8. JONES SA, SHINTON RA. Improving outcome in stroke patients with visual problems. *Age and Ageing*. 2006; 35:560-5.
9. WINDSOR RL WINDSOR LK. Hemianopsia: Loss of Half of the Visual field After Stroke or Traumatic Brain Injury.  
<http://www.lowvision.org/understanding%20hemianopsia1.htm>:accessed23/03/2014
10. ROWE FJ. Who sees visual impairment following stroke? *Strabismus*. 2010; 18; 37-40

11. POLLOCK A, HAZELTON C, HENDERSON CA, et al. Interventions for visual field defects in patients with stroke. *Cochrane Database of Systematic Reviews*. 2011 Oct 5;(10):CD008388. Review.
12. AIMOLA L, LANE AR, SMITH DT, et al. Efficacy and feasibility of home-based training for individuals with homonymous visual field defects. *Neurorehabilitation Neural Repair*. 2014; 28: 207-218
13. ROWE FJ, BARTON PG, BEDSON E, et al. A randomised controlled trial to compare the clinical and cost-effectiveness of prism glasses, visual search training and standard care in patients with hemianopia following stroke: a protocol. *BMJ Open* 2014; 4: e005885 doi: 10.1136/bmjopen-2014-005885
14. GIORGI RG, WOODS RI, PELI E. Clinical and laboratory evaluation of peripheral prism glasses for hemianopia. *Optometry and Vision Science*. 2009; 86: 492-502
15. LANCASTER GA, DODD S, WILLIAMSON PR. Design and analysis of pilot studies: recommendations for good practice. *Journal of Evaluation in Clinical Practice*. 2004; 10: 307-12
16. MORGAN TM, CASE LD. Conservative sample size determination for repeated measures analysis of covariance. *Annals of Biometrics and Biostatistics*, 2013; 1002: 1-6.
17. STIFTER E, KÖNIG F, BAUER P, et al. Reproducibility of measurements – statistical evaluation of the “Radner Reading Charts”. *Graefe Arch Klin Ophthalmol*. 2004 Jan;242:31-9.

18. RAPHAEL BA, GALETTA KM, JACOBS DA, et al. Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. *American Journal of Ophthalmology*. 2006; 142: 1026-35
19. LENNON S, JOHNSON L. The modified rivermead mobility index: validity and reliability. *Disability and Rehabilitation*. 2000; 15: 833-9
20. LINCOLN NB, GLADMAN JR. The extended activities of daily living scale: a further validation. *Disability and Rehabilitation*. 1992; 14: 41-3
21. BRAZIER JE, WALTERS SJ, NICHOLL JP, KOHLER B. Using the SF-36 and Euroqol on an elderly population. *Quality of Life Research*. 1996; 5: 195-204
22. GANDEK B, WARE JE, AARONSON NK, et al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. *International quality of life assessment. Journal of Clinical Epidemiology*. 1998; 51: 1181-8
23. ROWE FJ, CONROY EJ, BARTON P, et al. A randomised controlled trial of treatment for post-stroke homonymous hemianopia: screening and recruitment. *Neuro-Ophthalmology*. 2016; 40: 1-8
24. BOWERS AR, KEENEY K, PELI E. Community-based trial of a peripheral prism visual field expansion device for hemianopia. *Archives of Ophthalmology*. 2008; 126: 657-664


25. HEPWORTH LR, ROWE FJ, HARPER R, et al. Patient reported outcome measures for visual impairment after stroke: a systematic review. *Health and Quality of Life Outcomes*. 2015; DOI: 10.1186/s12955-015-0338-x
26. CHARLESWORTH G, BURNELL K, HOE J, ORRELL M, RUSSELL I. Acceptance checklist for clinical effectiveness pilot trials: a systematic approach. *BMC Medical Research Methodology*. 2013; 13: 1-

**Figure 1. Cumulative recruitment graph for all centres**



	Mar-11	Apr-11	May-11	Jun-11	Jul-11	Aug-11	Sep-11	Oct-11	Nov-11	Dec-11	Jan-12	Feb-12	Mar-12	Apr-12	May-12	Jun-12	Jul-12	Aug-12	Sep-12	Oct-12	Nov-12	Dec-12	Jan-13	Feb-13	Mar-13	Apr-13	May-13	Jun-13	Jul-13	Aug-13	
Expected Recruitment	2	6	12	19	25	31	37	43	49	56	62	68	74	80	86	93	99	105													
Revised Expected Recruitment																21	24	27	30	33	36	39	42	45	48	52	56	60	64	68	
Actual Recruitment			2	5	7	7	9	11	12	13	14	15	16	17	19	21	25	27	27	31	36	36	38	40	45	51	56	63	68	87	

**Figure 2. CONSORT 2010 Flow Diagram**



\*Complete withdrawal: patients withdrawn from all data analysis and follow up

# Partial withdrawal: patients withdrawn from follow up

**Table 1. Baseline demographic characteristics**

Baseline Characteristic	Treatment			Total
	Fresnel prisms	Visual search training	Standard care	
Patients Randomised	26	30	29	85
Age (years) Mean (SD), median (IQR), range	69.9 (12.9) 68.8 (14.4) 35.2 to 90.2	70.9 (11.2) 72.9 (15.2) 40.5 to 89.3	66.2 (11.3) 68.2 (16.2) 42.8 to 85.6	69.0 (11.8) 69.0 (15.3) 36.2 to 90.2
Gender, Male, n (%)	22 (84.6)	17 (56.7)	20 (69.0)	59 (69.4)
Ethnicity				
White n, (%)	25 (96.1)	30 (100.0)	28 (96.6)	83 (97.6)
Black n, (%)	1 (3.9)	0 (0.0)	1 (3.4)	2 (2.4)
Asian n, (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Mixed n, (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)



**Table 2. Baseline clinical characteristics**

Baseline Characteristic	Treatment			Total
	Fresnel prisms	Visual search training	Standard care	
Patients Randomised	26	30	29	85
Stroke onset (days from stroke to randomisation)				
Mean (SD)	75.5 (45.3)	73.8 (49.2)	81.2 (48.0)	76.9 (47.2)
Median (IQR)	64.5 (78.0)	69.0 (97.0)	67.0 (61.0)	67.0 (77.0)
Range	18.00 to 173.0	13.0 to 172.0	15.0 to 186.0	13.0 to 186.0
Stroke Type				
Ischaemic, n (%)	25 (96.2)	28 (93.3)	28 (96.6)	81 (95.3)
Haemorrhagic, n (%)	1 (3.8)	2 (6.7)	1 (3.4)	4 (4.7)
Side of infarct				
Left, n (%)	9 (34.6)	17 (56.7)	11 (37.9)	37 (43.5)
Right, n (%)	16 (61.5)	13 (43.3)	17 (58.6)	46 (54.1)
Bilateral, n (%)	1 (3.9)	0 (0.0)	1 (3.5)	2 (2.4)
Visual field assessment diagnosis:				
Homonymous hemianopia left partial, n (%)	8 (30.8)	5 (16.7)	8 (27.6)	21 (24.7)
Homonymous hemianopia right partial, n (%)	3 (11.5)	9 (30.0)	5 (17.2)	17 (20.0)
Homonymous hemianopia left complete, n (%)	9 (34.6)	8 (26.7)	10 (34.5)	27 (31.8)
Homonymous hemianopia right complete, n (%)	6 (23.1)	8 (26.7)	6 (20.7)	20 (23.5)
Bilateral hemianopia, n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Barthel index score				
Mean (SD)	97.5 (5.5)	92.7 (11.9)	93.3 (14.7)	94.4 (11.6)
Median (IQR)	100.0 (0.0)	100.0 (15.0)	100.0 (5.0)	100.0 (5.0)
Range	80.0 to 100.0	65.0 to 100.0	45.0 to 100.0	45.0 to 100.0

**Table 3. Sample size estimation – total number of patients with complete follow up required per arm (significance level= 0.05)**

		Type II error ( $\beta$ )		
		0.1	0.2	0.5
Estimated using data from all visual field assessment methods				
Minimally clinically important difference	200 degrees <sup>2</sup>	269	203	98
	400 degrees <sup>2</sup>	68	51	25
	600 degrees <sup>2</sup>	30	23	11
Estimated using data from modal visual field assessment method: Humphrey				
Minimally clinically important difference	200 degrees <sup>2</sup>	132	100	48
	400 degrees <sup>2</sup>	33	25	12
	600 degrees <sup>2</sup>	15	12	6

**Table 4. Descriptive statistics for visual field by group, time-point and assessment method**

<b>A: Baseline</b>	Treatment			
Timepoint <i>Perimetry method (degrees<sup>2</sup>)</i> Statistic	Fresnel prisms (N=26)	Visual search training (N=30)	Standard care (N=29)	Total (N=85)
Baseline				
<i>Confrontation</i>				
n	0	1	0	1
mean (sd)	NA	0.0 (NA)	NA	0.0 (NA)
missing	NA	0	NA	0
<i>Humphrey Static Esterman</i>				
n	13	14	12	39
mean (sd)	1382.5 (1190.3)	1428.9 (942.1)	955.8 (840.8)	1267.9 (1000.3)
missing	0	0	0	0
<i>Goldmann Kinetic Esterman</i>				
n	2	5	4	11
mean (sd)	779.5 (1102.4)	922.4 (1600.4)	894.3 (1541.9)	886.2 (1364.7)
missing	0	0	0	0
<i>Octopus Static Esterman</i>				
n	11	9	13	33
mean (sd)	1858.5 (1547.8)	1525.4 (1169.9)	2199.7 (1504.8)	1902.1 (1419.9)
missing	0	0	0	0
<i>Octopus Kinetic Esterman</i>				
n	0	0	0	0
mean (sd)	NA	NA	NA	NA
missing	NA	NA	NA	NA
<i>Other</i>				
n	0	1	0	1
<i>Not done</i>				
N	0	0	0	0

<b>B: 26 week follow up assessment</b>				
<i>Confrontation</i>				
n	0	1	0	1
mean (sd)	NA	3126.0 (NA)	NA	3126.0 (NA)
missing	NA	0	NA	0
<i>Humphrey Static Esterman</i>				
n	13	11	10	34
mean (sd)	1743.5 (1419.6)	1542.2 (778.9)	1165.8 (958.6)	1508.5 (1104.5)
missing	0	0	0	0
<i>Goldmann Kinetic Esterman</i>				
n	2	5	2	9
mean (sd)	1153.5 (686.6)	1792.4 (1940.3)	1736.5 (2160.2)	1638.0 (1612.7)
missing	0	0	0	0
<i>Octopus Static Esterman</i>				
n	9	8	10	27
mean (sd)	1738.4 (1498.2)	1897.6 (1527.3)	2101.3 (1514.0)	1920.6 (1461.6)
missing	0	0	0	0
<i>Octopus Kinetic Esterman</i>				
n	0	0	0	0
mean (sd)	NA	NA	NA	NA
missing	NA	NA	NA	NA
<i>Not done</i>				
n	2	5	5	14

0 represents complete homonymous hemianopia

6262 is the maximum visual field area score representing a normal hemifield

**Table 5. Relative change in visual field**

**A: by treatment group**

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean	
					Lower bound	Upper bound
Fresnel prisms	24	0.05247973	0.13958788	0.02849326	-0.00646	0.11142
Visual search training	24	0.08152371	0.14880363	0.03037441	0.01869	0.14436
Standard care	22	0.0352049	0.15023043	0.03202924	-0.03140	0.10181
Total	70	0.0570084	0.1453011	0.0173668	0.02236	0.09165

**B: ANOVA results for relative change in visual field (comparison across arms)**

Source	Sum of squares	DF	Mean Square	F-test	P- value
Treatment	0.02537506	2	0.01268753	0.59	0.5551
Error	1.43138058	67	0.02136389		
Corrected total	1.45675564	69			

**Table 6 VFQ outcome assessment**

**A: Descriptive statistics by group and time-point**

Timepoint Statistic	Treatment			Total (N=85)
	Fresnel prisms (26)	Visual search training (N=30)	Standard care (N=29)	
Baseline				
n	25	30	28	83
mean (sd)	68.5 (16.4)	60.0 (19.0)	63.7 (19.4)	63.8 (18.5)
median (IQR)	71.2 (62.1 to 76.9)	56.4 (44.5 to 78.8)	63.2 (44.6 to 77.2)	64.4 (47.0 to 77.7)
(min, max)	(19.8, 93.9)	(21.2, 96.0)	(35.0, 93.0)	(19.8, 96.0)
Not done	1	0	1	2
26 follow-up assessment				
n	24	25	19	68
mean (sd)	68.2 (18.4)	68.4 (20.0)	59.8 (22.7)	65.9 (20.3)
median (IQR)	70.1 (57.1 to 84.7)	73.4 (53.5 to 83.0)	63.9 (38.2 to 79.4)	68.9 (53.2 to 85.6))
(min, max)	(18.2, 96.5)	(25.5, 99.2)	(22.9, 95.2)	(18.2, 99.2)
Not done	2	5	10	17

**B: Analysis of Covariance (ANCOVA) results for changes in VFQ scores across arms**

*Patients who do not have VFQ data for baseline and/or 26 week follow up were not included*

Source	Sum of squares	DF	Mean Square	F-test	P-value
Baseline score	13368.70569	1	13368.70569	65.05	<0.0001
Treatment	1294.77789	2	647.38895	3.15	0.0497
Error	12947.44855	63	205.51506		
Corrected total	27610.93214	66			

## Parameter Estimates

Variable	Estimate	Standard Error	t-value	P-value
Intercept	10.02776246	6.92848157	1.45	0.1528
Baseline score	0.80599816	0.09875501	8.16	<0.0001
Visual Search Training	10.41706704	4.36870996	2.38	0.0201
Fresnel Prism	2.86798670	4.49330209	0.64	0.5256
Standard Care	0.00000000	.	.	.

**Table 7. Adverse events across groups**

Adverse event	Fresnel prisms (N=26)		Visual search training (N=30)		Standard care (N=29)	
Event	Events: n	Patients: n(%)	Events: n	Patients: n(%)	Events: n	Patients: n(%)
Difficulty with navigation	2	2 (7.7)	0	0 (0.0)	0	0 (0.0)
Diplopia	5	5 (19.2)	0	0 (0.0)	0	0 (0.0)
Dizziness	2	1 (3.8)	0	0 (0.0)	0	0 (0.0)
Fatigue	0	0 (0.0)	6	1 (3.3)	0	0 (0.0)
Headache	28	6 (23.1)	1	1 (3.3)	0	0 (0.0)
Optical glare/aberrations	1	1 (3.8)	0	0 (0.0)	0	0 (0.0)
Visual confusion	4	3 (11.5)	0	0 (0.0)	0	0 (0.0)
Total	42	18 (69.2)	7	2 (6.7)	0	0 (0.0)